BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,089,706 shares of the biopharmaceutical company's stock after selling 1,432,093 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.07% of Pfizer worth $103,633,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in PFE. Brighton Jones LLC increased its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the period. Freedom Investment Management Inc. increased its holdings in Pfizer by 67.5% during the fourth quarter. Freedom Investment Management Inc. now owns 31,737 shares of the biopharmaceutical company's stock valued at $842,000 after buying an additional 12,792 shares during the last quarter. Capital International Inc. CA raised its position in Pfizer by 10.6% in the fourth quarter. Capital International Inc. CA now owns 349,653 shares of the biopharmaceutical company's stock worth $9,276,000 after acquiring an additional 33,489 shares during the period. Finally, Ossiam boosted its stake in shares of Pfizer by 44.2% during the 4th quarter. Ossiam now owns 265,695 shares of the biopharmaceutical company's stock worth $7,049,000 after acquiring an additional 81,496 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently commented on PFE. Redburn Atlantic decreased their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Leerink Partners lowered their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Finally, Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $28.12.
Check Out Our Latest Stock Report on Pfizer
Pfizer Stock Performance
PFE opened at $25.16 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $143.05 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.89 and a beta of 0.52. The company has a fifty day moving average of $24.60 and a 200 day moving average of $24.42. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's payout ratio is presently 91.49%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access